These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 24326362)
21. Serine protease inhibitor 8 is a novel immunohistochemical marker for neuroendocrine tumors of the pancreas. de Koning PJ; Bovenschen N; Broekhuizen R; Lips CJ; Kummer JA Pancreas; 2009 May; 38(4):461-7. PubMed ID: 19188865 [TBL] [Abstract][Full Text] [Related]
22. Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding. Jehle PM; Jehle D; Fussgänger RD; Adler G Exp Clin Endocrinol Diabetes; 1995; 103 Suppl 2():31-6. PubMed ID: 8839251 [TBL] [Abstract][Full Text] [Related]
24. Exogenous expression of glucagon-like peptide 1 receptor and human insulin in AtT-20 corticotrophs confers cAMP-mediated gene transcription and insulin secretion. Sidhu KK; Fowkes RC; Skelly RH; Burrin JM J Endocrinol; 2005 Dec; 187(3):419-27. PubMed ID: 16423821 [TBL] [Abstract][Full Text] [Related]
25. Contribution of a PS1-like element to the tissue- and cell-specific expression of the human GLP-1 receptor gene. Galehshahi FS; Göke B; Lankat-Buttgereit B FEBS Lett; 1998 Oct; 436(2):163-8. PubMed ID: 9781671 [TBL] [Abstract][Full Text] [Related]
26. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225 [TBL] [Abstract][Full Text] [Related]
27. GLP-1 and glucagon secretion from a pancreatic neuroendocrine tumor causing diabetes and hyperinsulinemic hypoglycemia. Roberts RE; Zhao M; Whitelaw BC; Ramage J; Diaz-Cano S; le Roux CW; Quaglia A; Huang GC; Aylwin SJ J Clin Endocrinol Metab; 2012 Sep; 97(9):3039-45. PubMed ID: 22774207 [TBL] [Abstract][Full Text] [Related]
28. Development of a cysteine-deprived and C-terminally truncated GLP-1 receptor. Underwood CR; Knudsen LB; Garibay PW; Peters GH; Reedtz-Runge S Peptides; 2013 Nov; 49():100-8. PubMed ID: 24045233 [TBL] [Abstract][Full Text] [Related]
31. α-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness. Liu B; Tang LH; Liu Z; Mei M; Yu R; Dhall D; Qiao XW; Zhang TP; Zhao YP; Liu TH; Xiao Y; Chen J; Xiang HD; Wu HY; Lu CM; Lv B; Zhou YR; Zhang Y; Deng D; Chen YJ J Clin Endocrinol Metab; 2014 May; 99(5):E786-95. PubMed ID: 24483152 [TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors. Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213 [TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. During MJ; Cao L; Zuzga DS; Francis JS; Fitzsimons HL; Jiao X; Bland RJ; Klugmann M; Banks WA; Drucker DJ; Haile CN Nat Med; 2003 Sep; 9(9):1173-9. PubMed ID: 12925848 [TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271 [TBL] [Abstract][Full Text] [Related]
36. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors. Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786 [TBL] [Abstract][Full Text] [Related]
37. Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution. Dahdaleh FS; Calva-Cerqueira D; Carr JC; Liao J; Mezhir JJ; O'Dorisio TM; Howe JR Ann Surg Oncol; 2012 Mar; 19(3):966-72. PubMed ID: 21845496 [TBL] [Abstract][Full Text] [Related]
38. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series. Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939 [TBL] [Abstract][Full Text] [Related]
39. Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Koehler JA; Drucker DJ Diabetes; 2006 May; 55(5):1369-79. PubMed ID: 16644694 [TBL] [Abstract][Full Text] [Related]
40. GLP-1 could improve the similarity of IPCs and pancreatic beta cells in cellular ultrastructure and function. Shi Q; Luo S; Jia H; Feng L; Lu X; Zhou L; Cai J J Cell Biochem; 2013 Oct; 114(10):2221-30. PubMed ID: 23553680 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]